By Fineline Cube 
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance the application of small interfering RNA (siRNA) technology in the treatment of cardiovascular and cerebrovascular diseases. The collaboration aims to develop an innovative siRNA-based drug for chronic cardiovascular conditions, leveraging the unique advantages of siRNA technology to address current treatment challenges and provide patients with more effective and convenient therapeutic options.
siRNA Technology and Its Potential
siRNA drugs, an emerging therapeutic approach, offer strong targeting, long-lasting efficacy, and relatively shorter development cycles. They have demonstrated significant potential in treating metabolic disorders, cardiovascular diseases, neurological conditions, immune disorders, and viral infections. Anlong Biopharmaceutical brings its proprietary siRNA technology platform and extensive drug development experience, while Sun-Novo Pharmaceutical contributes its robust capabilities in drug discovery and commercialization. This collaboration combines their strengths to explore new frontiers in siRNA drug development.
Collaboration Goals and Impact
The partnership will focus on developing long-acting and highly efficient siRNA drugs to address issues such as poor treatment adherence in chronic cardiovascular diseases. By providing more precise and targeted treatment options, the collaboration aims to enhance patient outcomes and drive innovation in the field. The success of this initiative could pave the way for siRNA technology in other chronic disease areas, supported by the growing maturity and market acceptance of siRNA therapies.-Fineline Info & Tech